FHTX stock forecast, quote, news & analysis
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system... Show more
Why Foghorn Therapeutics (FHTX) Stock Is Down -51% in the Last 30 Days
Key Takeaways
- Foghorn Therapeutics (FHTX) shares have fallen roughly 51% over the last 30 days, dropping from about $4.14 to around $2.02.
- The decline was triggered by the October 1, 2026 announcement that Foghorn and Eli Lilly (LLY) would not advance the lead cancer candidate FHD-909 after Phase 1 data review.
- The two companies also discontinued a second collaborative program and ended further collaboration activities, prompting a roughly 40% workforce reduction.
- Multiple analysts downgraded the stock and slashed price targets, amplifying selling pressure.
- Foghorn is refocusing on its wholly owned preclinical pipeline and expects its cash runway to extend into the second half of 2029.
Foghorn Therapeutics (FHTX) Company Overview and Market Position
Foghorn Therapeutics Inc. is a clinical-stage precision biotechnology company headquartered in the Boston area. The company discovers and develops a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system—the network of proteins that controls gene expression and is implicated in a wide range of cancers.
Foghorn's core asset is its proprietary Gene Traffic Control platform, which enables the company to systematically study, identify, and validate drug targets within the chromatin regulatory system. The company's pipeline spans oncology as well as immunology and inflammation. Before the recent restructuring, its lead program was FHD-909, a selective SMARCA2 (BRM) inhibitor developed in collaboration with Eli Lilly's Loxo Oncology division for SMARCA4-mutated cancers. Investors have historically followed FHTX for its differentiated platform technology, its high-profile pharmaceutical partnerships, and the clinical progress of its lead programs.
Foghorn Therapeutics (FHTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, FHTX shares have declined approximately 51%, falling from a closing price near $4.14 to around $2.02. The decline was concentrated in early October, when the company announced the end of its Lilly collaboration and its restructuring plans.
The broader quarterly trend reflects an even steeper pullback. From a mid-July close of about $5.19, the stock has fallen roughly 61%. Shares rallied to a quarterly peak above $7.00 in mid-August before giving back those gains through September, as the stock drifted lower ahead of the anticipated readout of the FHD-909 Phase 1 dose-escalation data. The October announcement completed a sharp multi-month reversal that pushed FHTX to 52-week lows.
What Drove FHTX Stock Price in the Last 30 Days
The dominant catalyst was the October 1, 2026 disclosure that Foghorn and Eli Lilly had decided not to advance FHD-909 (LY4050784) into the clinical development expansion phase following a review of Phase 1 dose-escalation data. The companies also discontinued their Selective SMARCA2 degrader program and stated they did not anticipate further collaboration activities. CEO Adrian Gottschalk said the drug achieved selective SMARCA2 targeting with a favorable safety profile, but that the synthetic lethality biology did not translate into the efficacy required to advance the program.
Because the Lilly partnership was central to the investment thesis for the lead asset, the announcement triggered a sharp sell-off, with shares sliding sharply on elevated volume across multiple sessions. The company also announced an approximately 40% workforce reduction and a realignment of operating structure designed to extend its cash runway into the second half of 2029, reflecting a pivot away from the partnered program toward its proprietary pipeline.
Sell-side reactions compounded the pressure. Wedbush downgraded the stock to Neutral from Outperform and cut its price target to $2 from $10, while Citizens moved to Market Perform from Market Outperform. Additional firms, including TD Cowen, BTIG, Citi, and Evercore ISI, adjusted ratings and targets. A few analysts maintained positive ratings while reducing targets, including Guggenheim and H.C. Wainwright, citing long-term potential in Foghorn's wholly owned programs.
What Drove FHTX Stock Performance Over the Last Quarter
The quarterly decline reflects a broader shift in the company's risk profile. Through much of the summer, FHTX traded on the promise of its Lilly-partnered SMARCA2 program and the potential for near-term clinical catalysts. The stock climbed from roughly $5.00 in mid-July to above $7.00 in August amid preclinical data presentations and anticipation around the FHD-909 program.
That optimism unwound as the Phase 1 data review approached. Without a clear path forward for the lead asset, the market repriced the company from a partner-supported, late-stage-advancing story to an earlier-stage, fully preclinical pipeline. The end of the collaboration removed a significant source of external validation and potential milestone economics, and the 40% workforce reduction underscored the shift toward cash preservation. The result was a sustained repricing that erased the summer's gains and took the stock well below prior support levels.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently among the most relevant and top-performing on the platform. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only a focused group appears in this section based on performance and relevance. These bots vary considerably in trading strategy, timeframe, and performance metrics, giving traders a range of approaches to explore. For those interested in systematic, data-driven market analysis, the page offers a useful starting point to review which strategies are gaining traction.
FHTX Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investor attention will shift to Foghorn's wholly owned pipeline and its ability to translate its platform technology into clinical progress. Key programs include the Selective EP300 degrader, the Selective CBP degrader, a novel oral immunology and inflammation program, and the induced proximity platform. The company has indicated it is targeting Investigational New Drug (IND) applications for certain programs in 2027.
Additional factors to monitor include execution of the roughly 40% workforce reduction, the pace of spending following the restructuring, and whether the stated cash runway into the second half of 2029 remains intact. Macroeconomic conditions and broader biotech sentiment will also influence trading, as will any new preclinical data, partnership activity, or financing events. As a clinical-stage company, FHTX remains subject to the inherent risks of drug development, and these milestones should be assessed alongside the company's financial position rather than as a basis for investment decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
FHTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FHTX turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 33 of 35 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FHTX's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on FHTX as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.502) is normal, around the industry mean (3.037). P/E Ratio (-2.071) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology